Pimecrolimus: Novartis

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 720-724

  Schopf, Rudolf E ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN A; EMOLLIENT AGENT; PIMECROLIMUS; PLACEBO; TACROLIMUS; TAR;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CELL ACTIVATION; CLINICAL TRIAL; CREAM; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FOLLICULITIS; HEAT SENSATION; HUMAN; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; MAST CELL; NONHUMAN; PAIN; PSORIASIS; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN IRRITATION; T LYMPHOCYTE; TACHYPHYLAXIS; TELANGIECTASIA;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DERMATITIS; HUMANS; TACROLIMUS;

EID: 0036591234     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. 104101 Atopic dermatitis in infants and children. Hanifin JM Pediatr Clin North Am 1991 38 4 763-789
2. 208090 Clearing of psoriasis by a novel immunosuppressive macrolide. Rappersberger K, Meingassner JG, Fialla R, Fodinger D, Sterniczky B, Rauch S, Putz A, Wolff K J Invest Dermatol 1996 106 4 701-710
3. 251544 Brief comments on phase II data with Zelmac. Novartis AG Company Communication 1997 June 17
4. 319384 Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Van Leent EJM, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD Arch Dermatol 1998 134 805-809
5. 319386 The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E Br J Dermatol 1998 139 6 992-996
6. 319389 A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A Br J Dermatol 1997 137 4 568-576
7. 327313 Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthetized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J Arch Dermatol Res 1998 290 9 501-507
8. 338897 A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus multicenter atopic dermatitis study group. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S New Engl J Med 1997 337 12 816-821
9. 394812 Novartis. Merrill Lynch Capital Markets 2000 December 18
10. 411704 Novartis: Best foot forward. Merrill Lynch Capital Markets 2001 February 19
11. 412980 Novartis files Elidel (pimecrolimus, SDZ ASM 981), its novel treatment for atopic eczema, in the European Union- new cream offers hope for adults and children as young as three months. Novartis AG Press Release 2001 June 18
12. 415447 SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth Jones J, Bjerke J, Christophers E, Knop J, Knulst AC et al Br J Dermatol 2001 144 4 788-794
13. 415448 First experience of topical SDZ ASM 981 in children with atopic dermatitis. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P Br J Dermatol 2001 144 4 781-787
14. 415449 The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Queille Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP Br J Dermatol 2001 144 3 507-513
15. 415457 Atopic dermatitis in infants and children: An update. Kristal L, Klein PA Pediatr Clin North Am 2000 47 4 877-895
16. 415469 SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Quille Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, De Cuyper C, Ortonne JP Contact Dermatitis 2000 42 6 349-350
17. 421619 New non-steroid cream Elidel could change the treatment of eczema. Novartis AG Press Release 2001 September 07
18. 422674 Switzerland Pharmaceuticals - Novartis: Encouraging mix and momentum in H1. Deutsche Banc Alex Brown 2001 August 16
19. 433526 Novartis' eczema treatment, Elidel cream (Pimecrolimus), approved in the US. Novartis Pharmaceuticals Corp USA Press Release 2001 December 13
20. 434725 Pimecrolimus (Elidel®, SDZ ASM 981) cream 1%: A new approach to long-term management of atopic eczema in infants. Kapp A, Bingham A, De Moor A, De Prost Y, Papp K, Potter PC, Puig L, Molloy S, Thurston M, Cherill R, Graeber M J Eur Acad Derm Venereo 2001 15 Suppl 2 P2-14
21. 440183 Novartis Annual Report 2001: Advance copy. Novartis AG Annual Report 2002 February 14
22. 444009 Novartis' new non-steroid eczema treatment, Elidel cream, approved for use in babies to adults in Denmark. Novartis AG Press Release 2002 March 18
23. 444592 SG Cowen Securities Corp: The 22nd Annual Health Care Conference - Boston - March, 11th, 2002. Novartis AG Company Presentation 2002 March 11
24. 444664 The prevalence of childhood atopic eczema in a general population. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG J Am Acad Dermatol 1994 30 1 35-39
25. 444665 Worldwide variations in the prevalence of symptoms of atopic eczema in the International study of asthma and allergies in childhood. Williams H, Robertson C, Stewart A, Ait-Khale N, Anabwani G, Anderson R, Asher I, Beasley R, Bjorksten B, Burr M, Clayton T et al J Allergy Clin Immunol 1999 103 Pt 1 125-138
26. 444667 Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. Seymour JL, Keswick BH, Hanifin JM, Mordan WP J Am Acad Dermatol 1987 17 6 988-997
27. 444669 Pharmacoeconomics of drug therapy for atopic dermatitis. Lamb SR, Rademaker M Exp Opin Pharmacother 2002 3 3 249-255
28. 444670 A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winsiki A, Wolff B, Zenke G Br J Dermatol Suppl 1999 141 2 264-273
29. 444672 Low systemic exposure after repeated topical application of Pimecrolimus ((Elidel), SDZ ADM 981) in patients with atopic dermatitis. Van Leent EJM, Ebelin M-E, Burtin P Dermatology 2002 204 1 63-68
30. 444675 Diagnostic features of atopic dermatitis. Hanifin JM, Rajka G Acta Derm Venereol 1980 92 44-47
31. 444677 SDZ ASM 981 potently inhibits the induction of coreceptors involved in the accessory cell-dependent activation of inflammation-mediating T cells. Kalthoff E, Chung J, Grassberger M J Invest Dermatol 2001 117 Abs 440
32. 444678 Good skin tolerability of SDZ ASM 981 cream. Ebelin ME, Spake A, Heinrich U et al J Eur Acad Derm Venereo 1998 11 Suppl 2 S270
33. 444680 SDZ ASM 981 cream 1% is efficacious and safe in infants aged 3-23 months with atopic dermatitis. Ho V, Hedgecock S, Bush C J Invest Dermatol 2001 117 Abs 532
34. 444681 SDZ ASM 981 cream 1%: A new approach to long-term management of atopic dermatitis. Wahn U, Molloy S, Graeber M J Invest Dermatol 2001 117 Abs 533
35. 444684 Clinical experience with oral SDZ ASM 981 in psoriasis. Rappersberger K, Komar M, Ebelin ME et al J Eur Acad Derm Venereo 2000 14 Suppl 1 S255
36. 445230 The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, Henz BM J Allergy Clin Immunol 2001 108 2 275-280
37. 445692 Pimecrolimus (Novartis). Schopf RE Curr Opin Antiinflamm Immunomod Invest Drugs 1999 1 4 334-337
38. 445738 Effect of pimecrolimus cream 1% on quality of life and work productivity outcomes of patients with mild to moderate chronic hand dermatitis. Reilly MC, Lavin PT, Kahler KH Annu Meet Am Acad Dermatol 2002 60 Abs P209
39. 445742 Skin biopsy analyses of psoriasis patients treated with pimecrolimus (SDZ ASM 981) confirms reversal to normal phenotype. Rappersberger K, Richter L, Stuetz A, Wolff K Annu Meet Am Acad Dermatol 2002 60 Abs P109
40. 445747 Oral SDZ ASM 981: Clinical safety, tolerability, and efficacy in patients with moderate to severe chronic plaque psoriasis. Greig G, Burtin P, Wolff K Annu Meet Am Acad Dermatol 2001 59 Abs 512
41. 445750 Oral SDZ ASM 981: Pharmacokinetic profile in humans. Greig G, Burtin P, Scott G et al Annu Meet Am Acad Dermatol 2001 59th Meeting Abs 513
42. 445752 SDZ ASM 981 oral shows activity against murine allergic contact dermatitis, different from FK506 and cyclosporin A. Meingassner JG, Fahrngruber H, Bavandi A Annu Meet Am Acad Dermatol 2001 59 Abs 012
43. 446450 Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases. Herbert AA, Warken KA, Cherill R Seminars Cutaneous Med Surgery 2001 20 260-267
44. 448969 Novartis. Elidel seminar: Another Lamisil in the making. Moore DC et al Morgan Stanley Dean Witter 2002 January 10